Literature DB >> 27339732

Gut microbiota drive the development of neuroinflammatory response in cirrhosis in mice.

Dae Joong Kang1, Naga S Betrapally2, Siddhartha A Ghosh3, R Balfour Sartor4, Phillip B Hylemon5, Patrick M Gillevet2, Arun J Sanyal1, Douglas M Heuman1, Daniel Carl3, Huiping Zhou5, Runping Liu5, Xiang Wang5, Jing Yang5, Chunhua Jiao5, Jeremy Herzog4, H Robert Lippman6, Masoumeh Sikaroodi2, Robert R Brown2, Jasmohan S Bajaj7.   

Abstract

UNLABELLED: The mechanisms behind the development of hepatic encephalopathy (HE) are unclear, although hyperammonemia and systemic inflammation through gut dysbiosis have been proposed. The aim of this work was to define the individual contribution of hyperammonemia and systemic inflammation on neuroinflammation in cirrhosis using germ-free (GF) and conventional mice. GF and conventional C57BL/6 mice were made cirrhotic using CCl4 gavage. These were compared to their noncirrhotic counterparts. Intestinal microbiota, systemic and neuroinflammation (including microglial and glial activation), serum ammonia, intestinal glutaminase activity, and cecal glutamine content were compared between groups. GF cirrhotic mice developed similar cirrhotic changes to conventional mice after 4 extra weeks (16 vs. 12 weeks) of CCl4 gavage. GF cirrhotic mice exhibited higher ammonia, compared to GF controls, but this was not associated with systemic or neuroinflammation. Ammonia was generated through increased small intestinal glutaminase activity with concomitantly reduced intestinal glutamine levels. However, conventional cirrhotic mice had intestinal dysbiosis as well as systemic inflammation, associated with increased serum ammonia, compared to conventional controls. This was associated with neuroinflammation and glial/microglial activation. Correlation network analysis in conventional mice showed significant linkages between systemic/neuroinflammation, intestinal microbiota, and ammonia. Specifically beneficial, autochthonous taxa were negatively linked with brain and systemic inflammation, ammonia, and with Staphylococcaceae, Lactobacillaceae, and Streptococcaceae. Enterobacteriaceae were positively linked with serum inflammatory cytokines.
CONCLUSION: Gut microbiota changes drive development of neuroinflammatory and systemic inflammatory responses in cirrhotic animals. (Hepatology 2016;64:1232-1248).
© 2016 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2016        PMID: 27339732      PMCID: PMC5033692          DOI: 10.1002/hep.28696

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  37 in total

1.  Bile acid is a host factor that regulates the composition of the cecal microbiota in rats.

Authors:  K B M Saiful Islam; Satoru Fukiya; Masahito Hagio; Nobuyuki Fujii; Satoshi Ishizuka; Tadasuke Ooka; Yoshitoshi Ogura; Tetsuya Hayashi; Atsushi Yokota
Journal:  Gastroenterology       Date:  2011-08-10       Impact factor: 22.682

2.  Effect of lactitol and lactulose administration on the fecal flora in cirrhotic patients.

Authors:  O Riggio; M Varriale; G P Testore; R Di Rosa; E Di Rosa; M Merli; A Romiti; C Candiani; L Capocaccia
Journal:  J Clin Gastroenterol       Date:  1990-08       Impact factor: 3.062

3.  Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice.

Authors:  Magdalena Mazagova; Lirui Wang; Andrew T Anfora; Max Wissmueller; Scott A Lesley; Yukiko Miyamoto; Lars Eckmann; Suraj Dhungana; Wimal Pathmasiri; Susan Sumner; Caroline Westwater; David A Brenner; Bernd Schnabl
Journal:  FASEB J       Date:  2014-12-02       Impact factor: 5.191

4.  The importance of the small intestine in gut ammonium production in the fasting dog.

Authors:  F L Weber; G L Veach
Journal:  Gastroenterology       Date:  1979-08       Impact factor: 22.682

5.  Role of urea in the hyperammonemia of germ-free Eck fistula dogs.

Authors:  F C Nance; H J Kaufman; D G Kline
Journal:  Gastroenterology       Date:  1974-01       Impact factor: 22.682

6.  Hyperammonemic coma after hepatectomy in germ-free rats.

Authors:  S W Schalm; T van der Mey
Journal:  Gastroenterology       Date:  1979-08       Impact factor: 22.682

7.  Large-scale survey of gut microbiota associated with MHE Via 16S rRNA-based pyrosequencing.

Authors:  Zhigang Zhang; Huiqin Zhai; Jiawei Geng; Rui Yu; Haiqing Ren; Hong Fan; Peng Shi
Journal:  Am J Gastroenterol       Date:  2013-07-23       Impact factor: 10.864

8.  Network-based modeling of the human gut microbiome.

Authors:  Ammar Naqvi; Huzefa Rangwala; Ali Keshavarzian; Patrick Gillevet
Journal:  Chem Biodivers       Date:  2010-05       Impact factor: 2.408

9.  Metagenomic biomarker discovery and explanation.

Authors:  Nicola Segata; Jacques Izard; Levi Waldron; Dirk Gevers; Larisa Miropolsky; Wendy S Garrett; Curtis Huttenhower
Journal:  Genome Biol       Date:  2011-06-24       Impact factor: 13.583

10.  Statistical methods for detecting differentially abundant features in clinical metagenomic samples.

Authors:  James Robert White; Niranjan Nagarajan; Mihai Pop
Journal:  PLoS Comput Biol       Date:  2009-04-10       Impact factor: 4.475

View more
  27 in total

Review 1.  Gut microbiota in liver disease: too much is harmful, nothing at all is not helpful either.

Authors:  Phillipp Hartmann; Huikuan Chu; Yi Duan; Bernd Schnabl
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-02-15       Impact factor: 4.052

2.  Cholangiocyte-derived exosomal long noncoding RNA H19 promotes cholestatic liver injury in mouse and humans.

Authors:  Xiaojiaoyang Li; Runping Liu; Zhiming Huang; Emily C Gurley; Xuan Wang; Juan Wang; Hongliang He; Hu Yang; Guanhua Lai; Luyong Zhang; Jasmohan S Bajaj; Melanie White; William M Pandak; Phillip B Hylemon; Huiping Zhou
Journal:  Hepatology       Date:  2018-05-02       Impact factor: 17.425

Review 3.  Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders.

Authors:  Daniel M Chopyk; Arash Grakoui
Journal:  Gastroenterology       Date:  2020-06-20       Impact factor: 22.682

4.  Specific Gut and Salivary Microbiota Patterns Are Linked With Different Cognitive Testing Strategies in Minimal Hepatic Encephalopathy.

Authors:  Jasmohan S Bajaj; Andrew Fagan; Melanie B White; James B Wade; Phillip B Hylemon; Douglas M Heuman; Michael Fuchs; Binu V John; Chathur Acharya; Masoumeh Sikaroodi; Patrick M Gillevet
Journal:  Am J Gastroenterol       Date:  2019-07       Impact factor: 10.864

Review 5.  Animal Models of Alcoholic Liver Disease: Pathogenesis and Clinical Relevance.

Authors:  Bin Gao; Ming-Jiang Xu; Adeline Bertola; Hua Wang; Zhou Zhou; Suthat Liangpunsakul
Journal:  Gene Expr       Date:  2017-04-14

Review 6.  Microbiota, cirrhosis, and the emerging oral-gut-liver axis.

Authors:  Chathur Acharya; Sinem Esra Sahingur; Jasmohan S Bajaj
Journal:  JCI Insight       Date:  2017-10-05

7.  Brain Training with Video Games in Covert Hepatic Encephalopathy.

Authors:  Jasmohan S Bajaj; Vishwadeep Ahluwalia; Leroy R Thacker; Andrew Fagan; Edith A Gavis; Michael Lennon; Douglas M Heuman; Michael Fuchs; James B Wade
Journal:  Am J Gastroenterol       Date:  2016-12-13       Impact factor: 10.864

8.  The Psychometric Hepatic Encephalopathy Syndrome score does not correlate with blood ammonia, endotoxins or markers of inflammation in patients with cirrhosis.

Authors:  Nina Kimer; Lise Lotte Gluud; Julie Steen Pedersen; Juliette Tavenier; Søren Møller; Flemming Bendtsen
Journal:  Transl Gastroenterol Hepatol       Date:  2021-01-05

Review 9.  Role of the Gut Microbiota in Regulating Non-alcoholic Fatty Liver Disease in Children and Adolescents.

Authors:  Daisuke Tokuhara
Journal:  Front Nutr       Date:  2021-06-25

10.  Hepatic Branch Vagotomy Modulates the Gut-Liver-Brain Axis in Murine Cirrhosis.

Authors:  Yuan Zhang; Jason D Kang; Derrick Zhao; Siddartha S Ghosh; Yanyan Wang; Yunling Tai; Javier Gonzalez-Maeso; Masoumeh Sikaroodi; Patrick M Gillevet; H Robert Lippman; Phillip B Hylemon; Huiping Zhou; Jasmohan S Bajaj
Journal:  Front Physiol       Date:  2021-06-25       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.